文献速递细菌感染、耐药与抗菌药物

新型抗革兰阳性菌抗生素综述:现状与证据总结

New and improved? A review of novel antibiotics for Gram-positive bacteria.
PubMed 文献 · Clin Microbiol Infect · 2017-06-19

本叙述性综述通过检索MEDLINE和clinicaltrials.gov,汇总了近期获批或完成III期试验的、主要针对革兰阳性菌的新型全身性抗生素的疗效、抗菌谱和安全性证据。这些药物包括新型头孢菌素、脂糖肽类、氟喹诺酮类等,但其试验限于非严重感染,未显示优于标准治疗,安全性和药代动力学数据仍缺乏。

要点

  • 新型抗革兰阳性菌抗生素多仅在非严重感染中试验,病原体非以多重耐药为主。
  • 尚无新药显示优于标准治疗,也缺乏患者相关结局的研究。
  • 安全性和药代动力学数据仍不充分,临床定位尚未明确。

核心结论

  • 新型抗革兰阳性菌抗生素虽具前景,但现有证据限于非严重感染,未证明优于标准治疗,安全性和药代动力学数据缺乏,临床整合方式待确立。

研究设计与样本

  • 叙述性综述,通过MEDLINE检索已发表文献,并检索clinicaltrials.gov识别进行中的试验,必要时联系制药公司获取补充信息。

主要发现

  • 综述涵盖了新型头孢菌素(ceftaroline、ceftobiprole)、脂糖肽类(dalbavancin、oritavancin、telavancin)、氟喹诺酮类(delafloxacin、nemonoxacin、zabofloxacin)、二氢叶酸还原酶抑制剂iclaprim、截短侧耳素lefamulin和四环素omadacycline的数据。
  • 这些抗生素的试验限于非严重感染,治疗通常不复杂,病原体并非以多重耐药菌为主。
  • 没有任何新抗生素显示优于标准治疗,也没有针对患者相关结局进行研究。
  • 安全性和药代动力学数据持续缺乏。

临床怎么用

  • 临床使用这些新抗生素时需注意其证据限于非严重感染,不应视为优于标准治疗,且需关注安全性和药代动力学数据的不足。

局限性

  • 综述为叙述性,未提供系统评价方法;所纳入药物的试验多限于非严重感染,缺乏患者相关结局和安全性、药代动力学数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The number of antibiotics in the pipeline targeting Gram-positive pathogens has increased in recent years. AIMS: This narrative review aims to provide a summary of existing evidence on efficacy, microbiological spectrum and safety of novel systemic antibiotics that have either recently been licensed or completed phase III trials, and possess activity predominantly against Gram-positive organisms. SOURCES: A review of the published literature via the MEDLINE database was performed. In addition, ongoing trials were identified through a search of the clinical trial registration platform clinicaltrials.gov, and when necessary, pharmaceutical companies responsible for the development of the drug were contacted for further information. CONTENT: Data on development, microbiological spectrum, pharmacokinetic/pharmacodynamic properties, clinical efficacy, safety and cost are presented for the new cephalosporins ceftaroline and ceftobiprole; the lipoglycopeptides dalbavancin, oritavancin and telavancin; the fluoroquinolones delafloxacin, nemonoxacin and zabofloxacin; the dihydrofolate-reductase inhibitor iclaprim; the pleuromutilin lefamulin; and the tetracycline omadacycline. IMPLICATIONS: Although promising, these new antibiotics have so far been tested in non-severe infections whose treatment is generally uncomplicated and whose aetiologies were not predominantly multidrug-resistant pathogens. None of the new antibiotics have shown superiority to standard care, and none have been investigated for patient-relevant outcomes. Safety and pharmacokinetic data continue to be lacking. How these new drugs are to be integrated into the current armamentarium remains to be established.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Abbas M, Paul M, Huttner A, et al. New and improved? A review of novel antibiotics for Gram-positive bacteria. Clin Microbiol Infect. 2017. PMID: 28642145. doi:10.1016/j.cmi.2017.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。